average dose of semaglutide for weight loss Loss: How It Works, Comparisons, and More Semaglutide for Weight Loss: What

The EMA warned in October about falsified Ozempic injector pens identified at wholesalers in the EU and the UK

Resmetirom, which was also approved in August 2025 by the European Medicines Agency (EMA), is indicated for the treatment of adults with noncirrhotic MASH with moderate to advanced fibrosis and has been administered to over 23 000 patients in the USA ( On August 15th, 2025, the FDA granted an accelerated and conditional approval of the subcutaneous glucagonlike peptide (GLP1) receptor agonist (GLP1RA) semaglutide 2.4 mg/week for the treatment of MASH with moderate to advanced fibrosis (Stage F2F3) [7]

Giffi will raise when the data supports it

Genetic insights into MC4R and GIPR receptor variants can reveal which patients metabolize semaglutide more slowly or show heightened neural sensitivity, allowing providers to recommend slower titration or closer psychiatric monitoring where warranted

It has not received marketing authorisation from the MHRA or EMA and is not available as a licensed medicine in the UK